Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

97.6K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
97.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Molecular Profiling of Basal Cell Carcinomas in Sun-Exposed and Anogenital Regions.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2026
Same author

Immunotherapy in pediatric bone sarcomas: Current progress and future directions.

Human vaccines & immunotherapeutics·2026
Same author

Challenges of chimerism analysis using Next-Generation sequencing in a patient with complex chromosomal alterations.

Human immunology·2026
Same author

The registration status of maternal, newborn, and child health medical products: evidence from 9 countries.

Journal of pharmaceutical policy and practice·2026
Same author

Single-Cell RNA Analysis of Murine Osteosarcoma Uncovers Skp2 Function in Metastasis, Genomic Instability, and Immune Activation and Reveals Additional Target Pathways.

Cancer research communications·2026
Same author

Treatment strategies for relapsed medulloblastoma in the pediatric population: illustrative case.

Journal of neurosurgery. Case lessons·2026

Related Experiment Video

Updated: Jan 9, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.7K

Highly Sensitive Detection of Donor Chimerism by Next-Generation Sequencing.

Eros Qama1, Abedul Haque1, Juan Du1

  • 1Department of Pathology, Montefiore Medical Center, Bronx, New York.

The Journal of Molecular Diagnostics : JMD
|November 30, 2025
PubMed
Summary
This summary is machine-generated.

This study validates the One Lambda Devyser Chimerism assay, a sensitive next-generation sequencing test for monitoring donor chimerism after stem cell transplants. It accurately detects low levels of recipient DNA, aiding in early relapse detection.

More Related Videos

A Semiautomated ChIP-Seq Procedure for Large-scale Epigenetic Studies
08:04

A Semiautomated ChIP-Seq Procedure for Large-scale Epigenetic Studies

Published on: August 13, 2020

3.9K
Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
09:16

Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR

Published on: February 5, 2018

6.5K

Related Experiment Videos

Last Updated: Jan 9, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.7K
A Semiautomated ChIP-Seq Procedure for Large-scale Epigenetic Studies
08:04

A Semiautomated ChIP-Seq Procedure for Large-scale Epigenetic Studies

Published on: August 13, 2020

3.9K
Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
09:16

Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR

Published on: February 5, 2018

6.5K

Area of Science:

  • Hematology
  • Molecular Diagnostics
  • Genetics

Background:

  • Donor chimerism analysis is crucial for monitoring engraftment and relapse risk post-allogeneic stem cell transplantation.
  • Next-generation sequencing (NGS) assays offer improved sensitivity and accuracy over traditional methods like capillary electrophoresis.

Purpose of the Study:

  • To validate the performance of the One Lambda Devyser Chimerism assay, an NGS-based test for donor chimerism.
  • To assess the assay's sensitivity, specificity, and reliability in a diverse patient population.

Main Methods:

  • Validation of the One Lambda Devyser Chimerism assay using 270 clinical and cell-line DNA samples.
  • Correlation analysis with short tandem repeat (STR) assays.
  • Determination of analytical sensitivity (limit of blank, detection, quantitation) and specificity.
  • Evaluation of reproducibility, linearity, and DNA library characteristics.
  • Assessment of marker suitability in a cohort of 30 predominantly African American and Hispanic recipient/donor pairs.

Main Results:

  • High correlation (R² = 0.998) between the One Lambda Devyser assay and STR assays.
  • The assay reliably detects recipient DNA fractions as low as 0.1%, demonstrating high sensitivity.
  • Analytical specificity exceeded 99.9%.
  • An average of seven informative markers were identified per pair, with five for related pairs, in the tested diverse population.

Conclusions:

  • The One Lambda Devyser Chimerism assay is a highly sensitive and accurate NGS-based tool for donor chimerism monitoring.
  • The assay demonstrates excellent performance at low recipient DNA concentrations, enabling early detection of disease relapse.
  • The validation in a diverse population confirms its suitability for broad clinical application in stem cell transplantation monitoring.